Lastly, the availability of new phenotyping equipment such as the Oculus Keratograph 5M provides the opportunity for clinical parameters such as conjunctival redness and non-invasive tear break up time (NIBUT) to be assessed objectively, accurately and non-invasively [7]. To the best of the investigators' knowledge, these standardised tools have not been used in the context of rheumatological disease or its effect on the ocular surface.